Abstracts tagged "Inflammation"

Abstract Number: 1191 • ACR Convergence 2020
Specificity for Inflammatory Pathways Associated with Coronary Microvascular Dysfunction in Rheumatoid Arthritis
Brittany Weber¹, Zeling He¹, Sicong Huang¹, Daniel H. Solomon², Elena Massarotti¹, Charlotte Golnik¹, Thany Seyok¹, Seth Brownmiller¹, Laurel Martell¹, Leann Barrett¹, Courtney Bibbo¹, Marcy Bolster³, Marcelo DiCarli¹ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Concord, MA
Background/Purpose: Coronary microvascular disease (CMD) is associated with increased mortality in RA independent of traditional cardiovascular (CV) risk factors. Inflammation likely plays an important role…
Abstract Number: 1544 • ACR Convergence 2020
Tc99m Tilmanocept Imaging Is an Early Predictor of Clinical Response in Rheumatoid Arthritis Patients Beginning New Anti-TNFα Therapy
Mara Leach¹, David Ralph¹, Beth Potter¹, Bonnie Abbruzzese¹, Rachael Hershey¹, Jessica Fitzpatrick¹, Katherine Repp¹, Haya Shakhtra¹, Madison Palmer¹, Nicole Korczak¹, Audrey Villarosa¹, Michael Blue¹, Martin Jacobs², Yelliann Ruis³, Debbie Foley⁴, Alan Kivitz⁵ and Michael Rosol¹, ¹Navidea Biopharmaceuticals, Dublin, ²Kettering Medical Center, Kettering, ³Innovation Medical Research Center, Palmetto Bay, ⁴Premier Rheumatology of Oklahoma, Tulsa, ⁵Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA
Background/Purpose: Rheumatoid Arthritis (RA) is a serious and potentially debilitating disease, but low disease activity and even clinical remission can be obtained if an effective…
Abstract Number: 1931 • ACR Convergence 2020
Effect of Cumulative Glucocorticoid Dose and Inflammation on Weight Change During Treatment of Giant Cell Arteritis
Naomi Serling-Boyd¹, Xiaoqing Fu², Yuqing Zhang³, Sebastian Unizony¹, Zachary Wallace⁴, Hyon Choi⁵ and John H. Stone⁶, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Quincy, MA, ⁴Massachusetts General Hospital, Newton, MA, ⁵Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA, ⁶Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Giant cell arteritis (GCA) is a form of large vessel vasculitis that requires treatment with high-dose, long-term glucocorticoids (GC). Weight gain, among other side-effects…
Abstract Number: 0300 • ACR Convergence 2020
Exposure to Topical Antimicrobials Reduces Inflammatory Gene Expression in Cutaneous Lupus Lesional Skin
Sirisha Sirobhushanam¹, Allison Billi², Alex Tsoi², Celine Berthier², Johann Gudjonsson³ and J. Michelle Kahlenberg⁴, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, ³University of Michigan, Ann ArborUniversity of Michigan, ⁴Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Lupus lesional skin has elevated interferon expression, is highly colonized with Staphylococcus aureus (50%) and has no FDA-approved treatment options. S. aureus is known…
Abstract Number: 0653 • ACR Convergence 2020
Nutrient Content of Gout Flare Trigger Foods
Tanya Major¹, Ruth Topless¹, Elsa Sanchez-Lopez², Jennie Harré Hindmarsh³, Lisa Stamp⁴, Nicola Dalbeth⁵, Monica Guma⁶, Robert Terkeltaub⁷ and Tony Merriman¹, ¹University of Otago, Dunedin, New Zealand, ²University of California San Diego, San Diego, CA, ³Ngāti Porou Hauora, Te Puia Springs, New Zealand, ⁴University of Otago Christchurch, Christchurch, New Zealand, ⁵University of Auckland, Auckland, New Zealand, ⁶University of California San Diego, La Jolla, CA, ⁷VA/UCSD, San Diego, CA
Background/Purpose: A wide variety of foods are reported by patients to be triggers of gout flares. Some of these foods have been associated with serum…
Abstract Number: 0889 • ACR Convergence 2020
Efficacy of Secukinumab Treatment in Patients with Early Psoriatic Arthritis: A Pooled Analysis of 4 Phase 3 Studies
Christopher Ritchlin¹, Alan Kivitz², Peter Nash³, Renato Calheiros⁴, Xiangyi Meng⁵, Corine Gaillez⁶, Bruce Kirkham⁷ and Iain McInnes⁸, ¹Department of Medicine, University of Rochester Medical Center, Rochester, NY, ²Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA, ³School of Medicine Griffith University, Brisbane, Queensland, Australia, ⁴Novartis Pharmaceuticals Corporation, Hoboken, NJ, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ⁸Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) can progress quickly and lead to irreversible damage within 2 years of initial assessment if not treated.1 Secukinumab (SEC), a selective…
Abstract Number: 1217 • ACR Convergence 2020
Effects of JAK Inhibitors Against JAK2-mediated Signaling in Innate Immune Cells
Yuya Fujita¹, Naoki Matsuoka¹, Makiko Furuya-Yashiro², Jumpei Temmoku², Yuki Kuroiwa³, Masaru Tanaka⁴, Tomoyuki Asano², Shuzo Sato⁵, Haruki Matsumoto², Hiroshi Watanabe², Hideko Kuzuru⁶, Hiroshi Yatsuhashi⁷, Atsushi Kawakami⁸ and Kiyoshi Migita⁹, ¹Fukushima Medical University School of Medicine, Department of Rheumatology, Fukushima, Fukushima, Japan, ²Fukushima Medical University School of Medicine, Department of Rheumatology, Fukushima, Japan, ³Eli Lilly Japan K.K., Tokyo, ⁴Eli Lilly Japan K.K., Tokyo, Japan, ⁵Fukushima Medical University School of Medicine, Department of Rheumatology, Fukushima, Japan, ⁶NHO Nagasaki Medical Center, Clinical Research Center, Omura, Japan, ⁷NHO Nagasaki Medical Center, Clinical Research Center, Omura, Nagasaki, Japan, ⁸Nagasaki University Graduate School of Biomedical Sciences, Unit of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology, Nagasaki, Nagasaki, Japan, ⁹Fukushima Medical University School of Medicine, Department of Rheumatology, Fukushima, Fukushima, Japan
Background/Purpose: Janus kinase (JAK) family is comprised of JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2). JAKs form homo- or hetero-complexes, the combination of which…
Abstract Number: 1563 • ACR Convergence 2020
High Impact Sports Leads to Inflammatory Responses at Entheseal Sites Results of the BEAT Study (Badminton Enthesitis Arthrosonography Study)
David Simon¹, Arnd Kleyer¹, Koray Tascilar¹, Sara Bayat², Johannes Knitza³, Larissa Valor-Mendez⁴, Marina Schweiger⁵, Georg Schett⁶ and Axel Hueber⁷, ¹Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁴Department of Internal Medicine 3, Rheumatology and Immunology, University Hospital Erlangen, Erlangen, Bayern, Germany, ⁵Department of Internal Medicine 3, Rheumatology and Immunology, Erlangen, Germany, ⁶Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, ⁷Sektion Rheumatologie, Sozialstiftung Bamberg, Bamberg, Germany
Background/Purpose: Biomechanical stress triggers entheseal inflammation in psoriatic disease [1,2]. However, there is only limited data on the impact of mechanical stress on entheseal sites…
Abstract Number: 1948 • ACR Convergence 2020
Identification of Small Molecules with Efficacy as Steroid Sparing Suppression of Chemokine and Cytokine Production by Rheumatoid Arthritis Fibroblast-like Synoviocytes
Tadashi Hosoya¹, Nikunj Shukla², Yuya Fujita³, Shiyin Yao⁴, Fitzgerald Lao⁴, Hiroyuki Baba¹, Shinsuke Yasuda⁵, Howard Cottam⁴, Dennis Carson⁴, Tomoko Hayashi⁴ and Mary Corr⁶, ¹Department of Rheumatology, Tokyo Medical and Dental University (TMDU), Tokyo, Tokyo, Japan, ²Moores Cancer Center, University of California San Diego, San Diego, CA, ³Department of Medicine, University of California San Diego, San Diego, CA, ⁴Moores Cancer Center, University of California San Diego, San Diego, ⁵Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Tokyo, Japan, ⁶Department of Medicine, University of California San Diego, San Diego
Background/Purpose: Target-based drug discovery has expanded our therapeutic armamentarium in the treatment of inflammatory and autoimmune diseases. Despite these advances, glucocorticoids (GC) remain reliable agents…
Abstract Number: 0350 • ACR Convergence 2020
The Impact of Age and Time Since Diagnosis on Response to Treatment with Secukinumab in Pooled Week 52 Data from 4 Phase 3 Studies in Patients with Ankylosing Spondylitis
Atul Deodhar¹, Philip Mease², Paula Machado³, Effie Pournara⁴, Xiangyi Meng³, Vibeke Strand⁵ and Marina Magrey⁶, ¹Oregon Health & Science University, Portland, OR, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁶Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease involving the sacroiliac joints and spine and associated with pain, stiffness, and disability.1 A previous analysis…
Abstract Number: 0693 • ACR Convergence 2020
Effect of Physical Activity on Cartilage Degradation and Inflammation in Individuals with Lumbar Spinal Stenosis
Gustavo Almeida¹, Samannaaz Khoja², Lauren Terhorst³, Gwendolyn Sowa⁴, Sara Piva² and Michael Schneider², ¹Department of Physical Therapy, UT HEALTH SAN ANTONIO, San Antonio, TX, ²Department of Physical Therapy, University of Pittsburgh, Pittsburgh, PA, ³Department of Occupational Therapy, University of Pittsburgh, Pittsburgh, PA, ⁴Department of Physical Medicine and Rehabilitation, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Guidelines recommend 150 minutes a week in moderate-intensity physical activity (MPA) to improve health in individuals with chronic disease such as those with lumbar…
Abstract Number: 0945 • ACR Convergence 2020
Neutrophils Mediate Kidney Inflammation Following Acute Skin Exposure to UV Light
Sladjana Skopelja-Gardner¹, Joyce Tai², Xizhang Sun², Lena Tanaka², James Kuchenbecker², Tomas Mustelin¹ and Keith Elkon², ¹University of Washington, Seattle, WA, ²University of Washington, Seattle
Background/Purpose: Sensitivity to ultraviolet (UV) light affects up to 80% of SLE patients and can exacerbate systemic disease flares, including lupus nephritis (LN). Our findings…
Abstract Number: 1233 • ACR Convergence 2020
Use of Multi-Biomarker Disease Activity Scores to Compare Biosimilar Adalimumab-afzb (PF-06410293) with EU-Sourced Reference Adalimumab in a Phase 3, Randomized, Double-Blind Trial in Patients with Active RA
Jonathan Kay¹, Amy Bock², Noriko Iikuni³, Wuyan Zhang⁴ and Daniel Alvarez⁵, ¹University of Massachusetts Medical School, Worcester, MA, ²Pfizer, Cambridge, MA, ³Pfizer, New York, NY, ⁴Pfizer, New York, ⁵Pfizer, Collegeville, PA
Background/Purpose: Traditional efficacy endpoints of disease activity (DA) in studies of anti-rheumatic drugs can be confounded by subjective (patient-/physician-reported) assessments, comorbidities, and pre-existing joint damage.…
Abstract Number: 1569 • ACR Convergence 2020
Immune Related Adverse Events Related to Check Point Inhibitors Among Outpatients in an Academic Center
Bushra Akram¹, Aleena Itani¹, Mohammad Razaq², Samera Vaseer¹, Sara Vesely¹ and Pawan Acharya¹, ¹University of Oklahoma Health Sciences Center, Oklahoma City, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Immune check point inhibitors (ICIs) allow the body to recognize tumor cells as non-self, resulting in immune-cell mediated tumor cell destruction. These therapies have the…
Abstract Number: PP03 • ACR Convergence 2020
Connecting with Rheumatology Professionals and Thought Leaders Inspired the Creation of a New Program Focused on Relapsing Polychondritis (“RP”), a Rare Rheumatic Disease: Participating at ACR Annual Meetings Has Provided Exceptional Opportunities to Learn and Build Relationships
Nancy Linn¹, Catherine Bammert², David Bammert³ and Michael Linn⁴, ¹Relapsing Polychondritis Foundation, Palos Verdes Estates, CA, ²MD Anderson, Houston, TX, ³Relapsing Polychondritis Foundation, Houston, TX, ⁴Relapsing Polychondritis Foundation, New York, NY
Background/Purpose: In 2011, I was diagnosed with relapsing polychondritis ("RP"), a debilitating and sometimes fatal rheumatic disease that is characterized by inflammation of cartilage and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].